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Abstract
Tumors create a heterogeneous acidic microenvironment which assists their growth and which must be taken into account
in the design of drugs and their delivery. In addition, the acidic extracellular pH (pHe) is itself exploited in several
experimental techniques for drug delivery. The way the acidity is created is not clear. We report here the spatial organization
of key proton-handling proteins in C6 gliomas in rat brain. The mean profiles across the tumor rim of the Na
+/H
+ exchanger
NHE1, and the lactate-H
+ cotransporter MCT1, both showed peaks. NHE1, which is important for extension and migration of
cells in vitro, showed a peak 1.55 times higher than in extratumoural tissue at 0.33 mm from the edge. MCT1 had a broader
peak, further into the tumor (maximum 1.76 fold at 1.0 mm from the edge). In contrast, MCT4 and the carbonic anhydrase
CAIX, which are associated with hypoxia, were not significantly upregulated in the rim. The spatial distribution of MCT4 was
highly correlated with that of CAIX, suggesting that their expression is regulated by the same factors. Since protons
extruded by NHE1 diffuse away through extracellular clefts, NHE1 requires a continuous source of intracellular protons.
From the stoichiometries of metabolic pathways that produce or consume H
+, and the greater availability of glucose
compared to oxygen in most parts of a tumor, we support the classic view that most of the net proton efflux from C6
gliomas originates in glycolytic formation of lactate and H
+ inside the tumor, but add that some lactate is taken up into cells
in the rim on MCT1, and some lactate diffuses away, leaving its associated protons available to re-enter cells for extrusion on
NHE1. Therapeutic inhibition of NHE1, MCT1 or CAIX is predicted to affect different parts of a tumor.
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Introduction
For a systemically administered drug to act preferentially on a
tumor, the drug must recognize some specific characteristic of the
tumor. The most widely-exploited characteristic is the rapid
replication of DNA, which suffers from being shared by cells of the
bone marrow, gut and hair roots. Inhibition of angiogenesis has
given disappointing results in the long term [1]. Another specific
characteristic of tumors, which concerns us here, is their unusually
acidic extracellular pH (pHe). Most normal cells have an
intracellular pH (pHi) of 7.1–7.2 and are bathed by extracellular
fluid with a lower H
+ activity corresponding to a pH of 7.4. In
tumor cells, the transmembrane gradient of H
+ activity is reversed:
pHi can be greater than 7.3 [2–5], and pHe is typically in the
range 6.4–7.0 [6–12]. The acidic pHe contributes to the
invasiveness of tumors [2,10,11,13,14] and clinical trials are in
progress using a pro-drug that is cleaved in the acidic environment
to release an inhibitor of proton pumps [11]. Tumors overexpress
extracellular proteinases [15], and these too are being used, in
animal models, to target molecules by cleaving linkers and
activating cell penetrating peptides [16]. Available data suggest
that both the secretion and the catalytic activity of proteinases,
including matrix metalloproteinases (MMPs), are increased at
acidic pHs [17,18] and that they promote the progression of
tumors [19].
In addition to the unusual absolute value of pHe in tumors, the
unusual transmembrane pH gradient can also be exploited to
target drugs. Most simply, the pH gradient causes intracellular
accumulation of drugs that are weak acids, while weak bases tend
to be excluded (although the actual distribution may be dominated
by other processes, such as extrusion of the drug on a drug
transporter) [20–22]. More sophisticated use of the pH gradient
includes attaching a drug or a fluorescent marker to a pH-sensitive
carrier [23–25]. A different use that has been suggested for the
acidic pHe is to image it non-invasively by magnetic resonance
techniques as an aid to diagnosis or for following the effects of
therapy [8,26].
In order to optimize therapeutic strategies that exploit the acidic
pHe, or target the mechanisms underlying it, it would be useful to
understand what causes it. Extracellular H
+ ions can diffuse freely
through extracellular clefts and so the accumulation of H
+
represented by an acidic pHe can only be maintained if H
+ ions
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exported from, the tumor cells [10,27,28]. The main source is the
conversion of glucose to equal numbers of lactate-ions and H
+ ions:
C6H12O6=2C 3H5O3
2 + 2H
+ [29–31]. In the steady state, lactate-
must leave the cell at a rate equal to its production. Driven by their
concentration gradient, lactate-ions leave the cells in one-to-one
association with H
+ ions, either by diffusion of neutral lactic acid, or
on a cotransporter of the MCT class [31,32]. The isoforms MCT1
(SLC16A1) and MCT4 (SLC16A3) are upregulated in at least some
tumors [33,34]. In the steady state, the concentrations of products of
ancillary reactions, such as conversion of NAD to NADH, are
recycled so they do not contribute to any net flux of acid equivalents.
Hence, production of lactic acid decreases pHe without (in the steady
state) acid-loading the cells. Despite producing large amounts of
lactate, even in the presence of oxygen [29,30,35–37] parts of tumors
also oxidize glucose completely to CO2 [5,30]. In the steady state, all
the CO2generated must effectively leave the cell,and it can do this by
diffusion through the lipid membrane [38,39] or perhaps through
aquaporins [40]. On arrival in the extracellular space, CO2 reacts
with water in the presence of carbonic anhydrase (CO2 +
H2O=H
+ + HCO3
2) and thereby makes a contribution to
extracellular acidity [5]. CO2 is also in equilibrium with H
+ and
HCO3
2 within the cell, so if HCO3
2 were to continually leave the
cell, oxidative metabolism would tend to decrease pHi. However,
HCO3
2 is generally transported into, rather than out of, cells [41,42]
and removal of CO2/HCO3
2increasespHiinU118gliomacells[2].
The synthesis from glucose and glutamine of molecules for cell
growth appears in most cases to consume H
+ (see Discussion). Thus
the net effect of metabolism, in conjunction with export of its
products, appears not to decrease pHi in the steady state, but it does
decrease pHe.
However, the unusual inward gradient of [H
+] into tumor cells
subjects them to an abnormally large influx of acid equivalents
that leak through ion channels or are carried on imperfectly
specific transporters. It is therefore unsurprising that mechanisms
for exporting acid equivalents are upregulated in tumors.
Upregulation has been reported of the Na
+/H
+ exchanger
NHE1 (SLC9A12, ref. [3]), and of the plasma membrane V-H
+-
ATPase [43]. NHE1 is interesting because numerous studies have
shown that in cancer cells growing or migrating in vitro it is
concentrated at the leading edge of "invadopodia" [3,44–47].
NHE1, which is the primary regulator of pHi in almost all normal
cells, uses the inward electrochemical gradient of Na
+ to extrude
protons. Its greater activity at the leading edge of migrating cells
causes a local increase in pHi and a decrease in pHe, both of
which promote cell extension [46]. Raised pHi remodels the
cytoskeleton, while lowered pHe modifies attachment to substrate
and disrupts extracellular matrix [46,48]. In addition to modifying
pH, the NHE1 molecule contributes to cell migration by
interacting directly with other macromolecules [47,49]. Inhibition
of NHE1 slows tumor growth [3,50,51]. These results suggest that
in tumors in vivo, NHE1 may have a role beyond regulation of pHi
and might be concentrated near the growing borders. As part of
the present work, we tested this hypothesis for the case in a rat
model of glioma, grown from the C6 cell line.
If NHE1 is extruding protons and creating a locally acidic pHe,
then where do these protons come from? (They cannot simply re-
enter the cell close to where they are extruded as this would
destroy the acidic pHe.) Sonveaux et al [14] provide a hint: they
showed that in SiHa tumors, MCT1 is highly expressed in the rim
of the tumor, where the energy metabolism is likely to be
oxidative. They suggest that here MCT1, instead of exporting
lactate, takes it up, as a substrate for oxidative metabolism. They
do not discuss proton fluxes, but protons will presumably
accompany lactate. Although, as we shall show in the Discussion,
these protons do not constitute the internal source for NHE1,
Sonveaux et al [14] do introduce the idea of fluxes between tumor
cells. We have therefore compared the spatial distribution of
MCT1 in C6 rat gliomas to that of NHE1.
To obtain a fuller picture, we also looked at two other proteins
associated with H
+ transport. These are the MCT isoform, MCT4
(SLC16A3), which is present on astrocytes [52], can be induced by
hypoxia via the Hypoxia-Inducible Factor 1a (HIF-1a [34]), and is
upregulated in parts of some tumors [53,54]. We have also looked
at an isoform of the enzyme carbonic anhydrase, CAIX, which is
also upregulated in vitro by HIF-1a and, like MCT4, has been
found in hypoxic parts of tumors [55–60]. Carbonic anhydrases,
which catalyse the reaction H
+ + HCO3
2=CO 2 + H2O, can
facilitate the diffusion of proton equivalents through extracellular
space [5,61]. The presence of a carbonic anhydrase close to an H
+
transporter can increase the transporter’s efficacy [62].
Our results show that gene expression in the growing border of
a C6 glioma is spatially organized and confirm the hypothesis that
expression of NHE1 is upregulated in the growing rim of a tumor
in vivo. We also also introduce a new technique for identifying pairs
of proteins whose expression is regulated by common factors.
Taken together with stoichiometric constraints, and the knowledge
that low pHe favors tumor growth, the results suggest that lactate
and H
+ ions flow between cells in a way that is a compromise
between efficient use of oxygen and glucose for cell growth, and
the creation of localized pH microenvironments.
Results
NHE1 and MCT1 peak in the tumor rim
Coronal brain sections were selected that passed approximately
through the equator of the C6 gliomas; the shorter diameters
ranged from 1.94 to 8.0 mm (Fig. 1 A–C). In general, on each
section, we stained nucleic acids with Hoechst 33342 and
immunolabeled two of four proteins involved in proton transport:
NHE1, MCT1, MCT4 and CAIX. The mean labeling intensities
of large regions of interest (ROIs) within each labeled glioma were
compared to the mean intensities in extratumoral tissue. The
ratios were as follows. NHE1: mean =1.15, s.e.m. =0.10, n=10
tumors, P for difference from 1=0.15. MCT1: 1.39260.078, n=
10, P=0.0007. MCT4: 1.3460.18 n=8, P=0.105. CAIX:
1.1460.14 n=7, P=0.36. Note that only for MCT1 was the
ratio significantly greater than 1. All four proteins were detected in
both normal brain and in the gliomas. Increased Hoechst labeling
near the perimeters of the gliomas was evident (Figs 1B,C). For
none of the four proteins was a convincing pattern of labeling
apparent on visual inspection of the tumor rim, but patterns
became evident on measured intensity profiles. In each section, we
selected 1–3 sites on the tumor border where the Hoechst staining
indicated a well-defined rim confronting neuronal tissue (rather
than the brain surface). We imaged rows of 10–20 microscope
fields to give composite images of bands of tissue each 387.5 mm
wide with their long axes perpendicular to the border. The "tile
scan" corresponding to the narrow rectangle in Fig. 1C is shown in
Fig. 1D for the Hoechst fluorescence, and the part of this covering
the glioma rim is expanded in Fig. 1E together with the
corresponding images for NHE1 and MCT1. The intensity
profiles along the images for each band were measured. We
defined the edge of the tumor to be where the rise in Hoechst
staining began (Figs. 1F,G, 2A). In almost all cases, NHE1
immunofluorescence showed a peak 0.25 – 0.4 mm into the tumor
(Fig. 1F). We obtained 22 NHE1 profiles from 10 tumors,
normalized each one so that the average intensity over 1 mm
Proton Transporters in Brain Tumor
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No profiles were excluded from analysis.
In the mean NHE1 profile (Fig. 2B), the peak is well-defined. In
contrast, the mean intensity of CAIX labeling showed no significant
change across the rim (Fig. 2C). This absence of a peak in CAIX
labeling suggests that the NHE1 peak was not an artifact, due, for
example, to uneven tissue shrinkage. (In agreement with reports on
other types of tumor, more intense CAIX labeling was present in
small areas deep in the tumor, in tissue that was probably hypoxic
[see 63]) The distance from the tumor edge of the NHE1 peak
varied somewhat between individual profiles, so when the profiles
were averaged (to give Fig 2B) the peak was somewhat flattened out.
To avoid this, we also measured the peak amplitude and its position
on the individual profiles, obtained average values for each tumor
and calculated the overall means. Calculated in this way, the mean
intensity of the NHE1 peak was 1.55 times the intensity outside the
tumor (SEM=0.10, n=10 tumors, P=0.0005). This figure still
slightly underestimates the true difference in the expression of
NHE1 protein between the peak and extratumoral tissue because
no correction was made for non-specific labeling by the secondary
antibody (see Supporting Information, Text S1, Figure S1). The
anti-NHE1 peak was on average 0.33060.027 mm from the edge.
This position was not significantly different from the mean position
of the Hoechst peak (0.37960.029 mm).
Labeling of MCT1, which can transport lactate and H
+ either
out of or into cells [64], peaked near the rim (Fig. 2D); the average
distance of the MCT1 peak from the edge was 1.0560.14 mm (9
gliomas) significantly greater than the distance of the NHE1 peak
(P=0.0001). Mean values for the peaks and their distances from
the tumor edge for Hoechst, NHE1 and MCT1 are shown in
Fig. 2F. For MCT4, as for CAIX, we did not detect a significant
increase in labeling in the rims of these gliomas (Fig 2E). The
means of the ratios of the intensity at 1 mm from the edge to the
intensity outside were, for MCT4, 1.31, S.D.=0.47, n=8 and, for
CAIX, 1.17, S.D.=0.35, n=7.
MCT4 and CAIX are spatially correlated
Profiles of labeling intensity for MCT4 and CAIX, unlike
NHE1 and MCT1, showed no clear organization at the rim of the
Figure 1. Immunofluorescence profiles across the tumor border. (A) A section of a small C6 glioma stained with haemotoxylin-eosin; (B) part
of an adjacent section with nucleic acids stained with Hoechst 33342. (C) Another glioma stained with Hoechst and showing a strip crossing the
border that was tilescanned. (D) The Hoechst tilescan of the strip indicated in (C). (E) Portions of the tilescan for Hoechst (blue) NHE1 (red) and MCT1
(green). (F) Intensity profiles of the strips in (E) with positive distances directed into the glioma. From the Hoechst profile, it was possible to identify
the approximate position of the tumor border on the micrographs (arrows in D and E). (G) Intensity profiles from another section labeled for MCT4
showing it does not increase markedly in the rim.
doi:10.1371/journal.pone.0017416.g001
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pixel by pixel comparison (pixel size 0.76 – 1.5 mm). However, on
the larger scale of the 0.3875 mm wide bands, the intensity of the
two tended to vary in parallel, both outside and inside the tumors,
as illustrated in Fig. 3A. From the data that gave Fig. 3A, and
other similar profiles, we plotted the intensity of CAIX for each
data point against the corresponding intensity of MCT4 at the
same spatial position. The points lay close to a straight line
characterized by a correlation coefficient r
2 close to one (Fig. 3
B,F). Part of this correlation is simply due to irregularities in the
structure of the tissue in the sections. However, the correlation
between the intensities of the unspecific labeling by the pairs of
secondary antibodies in the absence of primary antibodies was
significantly lower (Fig. 3 C,F). And correlation between Hoechst
labeling and each of the proteins was low, even in the case of anti-
NHE1 labeling and Hoechst labeling, which peak at about the
same distance from the edge (Fig. 3 D,F). The relation between
MCT1 and NHE1 may have reflected differences between the
intra- and extratumoral compartments (Fig. 3 E); when the
average Pearson correlation coefficient was calculated, it was
significantly less than for the pair CAIX-MCT4 (Fig. 3F). Mean
correlation coefficients were calculated for profiles from each
tumor with the appropriate labeling and the averages for the
tumors were calculated (Fig. 3F). The mean correlation for CAIX/
MCT4 was significantly higher than for the other pairs of labels.
Discussion
The tumor rim is structured
The present results show that certain proteins are expressed in
an organized way in the rim of a C6 glioma that confronts non-
tumoral tissue of the brain parenchyma. Expression of the Na
+/H
+
exchanger, NHE1, peaks at about 0.3 mm in from the edge,
MCT1 has a broader peak with a maximum at about 1 mm, and,
Figure 2. Organization of NHE1 and MCT1 in the tumor rim. (A – E). Labeling intensity (relative to outside the glioma) for Hoechst (average of
27 strips), NHE1 (22), CAIX (22), MCT1 (18) and MCT4 (16). Gray lines are an indication of SEM (see Methods). Note that the ordinate scales are not all
the same. (F) Mean relative intensities 6 SEM for peaks (Hoechst, NHE1 and MCT1) and values at 1 mm for Hoechst and NHE1. Schematic curves have
been sketched in. The mean values were calculated from measurements on individual profiles and therefore do not correspond exactly with the
averaged profiles in (A,B,D).
doi:10.1371/journal.pone.0017416.g002
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the rim (Fig. 2). The organized distribution of NHE1 and MCT1
prompts consideration of how these proteins might be involved in
fluxes of lactate and protons within tumors. Protons can be
transported through tissue in many ways. In extracellular and
intracellular fluid, protons can be effectively transported as H3O
+
ions, or on diffusible pH buffer molecules [65]. Movement of CO2,
or, in the reverse direction, of HCO3
2, is also tantamount to a flux
of protons. Effective proton transport across membranes can be
mediated by ion channels and H
+ transporters (such as NHE1 and
the MCTs) and also by passage of CO2, or, in the reverse
direction, by HCO3
2. For brevity, we will generally use ‘‘proton
transport’’ to cover all these processes.
NHE1 expression is upregulated near the edge of the
tumor
In ‘‘invadopodia’’ of cells in culture, NHE1 molecules interact
with intracellular and extracellular structural proteins to contrib-
ute to cell migration. NHE1 also increases pHi and, provided
there is a source of intracellular protons to be extruded, decreases
pHe, leading to remodeling of the cytoskeleton, dismantling of the
extracellular matrix, and cell migration and division [66]. Our
observation that expression of NHE1, together with labeling of
nucleic acids, peaks near the edge of the C6 glioma, would appear
to be compatible with NHE1 having these functions in vivo.
The factor by which the number of NHE1 molecules per unit
area of membrane is increased in the rim of a C6 glioma is difficult
to estimate. The long, fine, processes that greatly increase the
membrane areas of neurons and astrocytes, are much reduced in
glioma cells. Because of this difference, a given number of NHE1
molecules per unit volume of tissue would correspond to a higher
number per unit area of membrane in the glioma than outside it.
A contrary tendency arises from the smaller volumes of the glioma
cells, particularly in the rim, as evidenced by the greater density of
nuclei (e.g., Figs 1 F,G, 2A). However, whatever the area of
membrane, an increased number of NHE1 molecules per unit
Figure 3. Profiles of CAIX and MCT4 are correlated. (A) Profiles of the intensities of labeling of CAIX and MCT4 along a sample strip 0.3875 mm
wide passing through extratumoral tissue and a C6 glioma. The brightness values were scaled to give considerable overlap of the two profiles. (B) The
values for CAIX and MCT4 in (A) are highly correlated. (C) The intensity profiles of the secondary antibodies in the absence of primaries show less
correlation (ordinate, green fluorescent secondary; abscissa, red fluorescent secondary). (D) NHE1 labeling correlates only weakly with Hoechst
labeling. (E). There is moderate correlation of MCT1 with NHE1. (A,B,D,E) are from the same glioma. (F) Average values of r
2. First column from 8
glioma-bearing brains; other columns from 4,6 and 7 brains respectively (sections labeled for the appropriate pairs were not made for all brains).
doi:10.1371/journal.pone.0017416.g003
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unit volume. In vitro, NHE1 expression can be upregulated by
BAX inhibitor 1 [67] and its activity is increased by epidermal
growth factor [3,48].
The role of MCT1
Extreme hypoxia prevents the oxidation of pyruvate in
mitochondria and most of the pyruvate produced by glycolysis is
then converted to lactate. Cancer cells in culture, and tumors as a
whole, also produce much lactate even when oxygen is available
[29,30,68]. In exercising striated muscle, it is well established that
lactate, exported from white fibers (with predominantly glycolytic
metabolism), is taken up on the MCT1 transporter by red fibers
with a predominantly oxidative metabolism [32]. Sonveaux et al
[14] found that MCT1 is upregulated in the rim of SiHa tumors,
and that SiHa cells in culture show considerable oxidative
metabolism. They suggest that lactate released by cells in hypoxic
regions of SiHa tumors is taken up into cells near the edge of the
tumor, which, being relatively close to the blood vessels in normal
tissue, may receive enough oxygen to oxidize lactate. The peak in
MCT1 in the rim of C6 gliomas would allow a similar transfer of
lactate from hypoxic to oxygenated regions. Tumors showing this
arrangement might prosper. Glucose, about 5 mM in blood, is
more plentiful than oxygen, which has a concentration of no more
than 2.5 mM in blood (mainly in hemoglobin) and much less in
tissue. More oxygen than glucose is required for oxidation of
glucose (6 molecules of oxygen per glucose) and, for a parasitic
tumor, glucose has no ‘‘cost’’, while adequate oxygenation deep
into a tumor requires the growth of a well-perfused neo-
vasculature. Hence, tumors that consume oxygen and lactate in
the rim and allow glucose to diffuse deeper into the tumor might
grow more rapidly than those that lack this arrangement.
Creation of an acidic microenvironment
Where do the protons extruded by NHE1 in the rim of the
tumor come from? Since an extracellular accumulation of H
+ will
dissipate by diffusion of H
+ through extracellular space [10,28], a
tumor, as a whole, can only maintain an acidic pHe by constantly
extruding protons (or some equivalent process, such as constantly
taking up HCO3
2). Any cyclic process whereby protons enter the
cell from the extracellular space and are then extruded at almost
the same place would not change pHe: the protons must be
generated within the cell (or come from other cells – see below). A
major source of intracellular H
+ ions is glycolytic production of
lactate. Lactic acid and its precursor, pyruvic acid, are .99%
unprotonated at physiological pHs [69]; the stoichiometry of
glycolysis for these unprotonated forms is shown in Fig. 4A and it
is seen that, in the steady state (when the concentrations of NADH,
NAD
+, ADP, ATP etc. remain constant), lactate ions and H
+ ions
are produced in equal numbers. Extracellular lactate diffuses away
through extracellular clefts, so an outwardly directed gradient of
[lactate
2] is created which drives the equimolar cotransport of H
+
[31]. Since each lactate
2 crosses the cell membrane in association
with a proton, glycolysis does not subject the cell to continuous
loading with internally-generated protons, and is not a direct
source of protons for other transporters such as NHE1.
Complete oxidation of glucose produces CO2 and H2O.
Normally the net flux of CO2 is exported by diffusion, and does
not lead to production of intracellular H
+ (Fig. 4A). In principle,
CO2 and H2O can react within the cell to produce bicarbonate
and H
+ ions and if the bicarbonate is exported, this is a potential
source of intracellular protons [5]. However, in the extracellular
space, bicarbonate will recombine with H
+, thereby tending to
increase pHe and negate the effects of proton extrusion. Hence, to
a first approximation, oxidative phosphorylation is not a useful
source of intracellular protons for producing an acid pHe.
Synthesis of the components of growing cells, such as fatty acids
and proteins, will, in general, be associated with net incorporation
of protons [69]. We have not found measurements relating to this,
but an extreme possibility for the stoichiometry of saturated fatty
acid synthesis from glucose is: (n+2) C6 H12O6 + 12n H R 6(CH3-
(CH2)n-CO2H) + 6nH2O; i.e., a considerable consumption of
protons. Hence, growing and dividing cells, which particularly
require a source of protons for extrusion on NHE1, also require
protons for anabolism.
The spatial organization of proton fluxes
Tumors release lactate to the blood stream, even though (at least
in the case of human colonic carcinomas) the tumor as a whole
fails to extract all the available oxygen from the blood [30].
Transformation of a stem cell into a successful tumor is such a rare
event that it is possible for tumor cells to differ from normal cells in
ways that are complex and apparently coherent in favoring tumor
growth [70,71]. A consequence beneficial to the tumor of releasing
lactate, rather using it all to produce large amounts of ATP in the
TCA cycle, or to provide hydrocarbon backbones for the synthesis
of macromolecules, is the provision of the associated protons to
create the acidic microenvironment that promotes growth. The
present results, showing a peak of NHE1 expression in the tumor
rim, suggest a refinement. H
+ ions diffusing through extracellular
Figure 4. Roles of MCT1 and NHE1 in C6 gliomas. (A)
Stoichiometry of the main pathways of glucose metabolism. Note that
the protons associated with lactate production are exported by
cotransport with lactate. The consequences of CO2 production are
potentially more variable than shown. (B) Scheme of fluxes of glucose,
oxygen, lactate and H
+ in the glioma rim, suggested by the profiles of
NHE1 and MCT1. Some of the lactate exported from deeper, hypoxic
regions is taken up on MCT1 in the rim of the tumor and oxidized to
CO2. Ground colors indicate pHe: red is acid, green is alkaline.
doi:10.1371/journal.pone.0017416.g004
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transporters or through ion channels and are then available for
extrusion on NHE1. This arrangement would not change the total
number of H
+ ions in the extracellular space, but would create the
localized decreases in pHe (and increases in pHi) that are part of
the processes of cell extension and division [46,48]. Since the
protons were produced in association with lactate, excess lactate
would diffuse out of the tumor. In contrast, if protons are taken up
into rim cells by cotransport with lactate and the lactate is oxidized
to CO2 and H2O, then the stoichiometry of the reaction requires
that these protons are consumed and unavailable for export on
NHE1. We are therefore suggesting a conceptual division of the
influx of protons into cells in the rim. Some protons enter in
association with lactate on MCTs, particularly MCT1, and are
consumed in the oxidation of lactate to CO2; others enter by other
routes and are extruded on NHE1 (Fig. 4B).
MCT4 and CAIX
Weak CAIX immunoreactivity was found throughout the brain
parenchyma, as has been reported by others [72]. Expression in
the glioma rim was variable, and on average, not significantly
different from extratumoral tissue [56,59]. Like CAIX, MCT4 was
present throughout the parenchyma, in accordance with its
reported presence in astrocytes [52]. As in SiHa and Wdr tumors
there was little overall upregulation [14]. Strikingly, there was
close correlation in space between MCT4 and CAIX on the large
scale of hundreds of microns (Fig. 3B,F), but not on a finer scale of
microns. In vitro, expression of both CAIX and MCT4 is increased
by HIF-1aA common upregulatory mechanism, perhaps acting
via HIF-1a, might lead to the observed spatial correlation. A close
spatial association between a pair of other isoforms of these
proteins, MCT1 and CAII, has been reported [62,73]. CAXII as
well as CAIX is upregulated in tumors, and six other known
isoforms are present in the brain [74], so our sampling of only
CAIX tells us little about the distribution of total CA activity.
Implications for cancer therapy
Inhibition of either MCT1 or NHE1 has been shown to slow
tumor growth in animal models [14,50,51]. In our proposed
scheme (Fig. 4B), the cells at the rim of the tumor use NHE1 to
create the low pHe that favors their extension, migration and
proliferation. MCT1 supports not only outward but also inward
fluxes of lactate involved in the supply of the hydrocarbon
elements necessary for growth, the ATP necessary to maintain
proton extrusion, and the protons themselves. NHE1, MCT1, and
associated proteins may be molecular targets worth investigating
further.
Conclusion
The arrangement of NHE1 and MCT1 in the rim of C6
gliomas adds to arguments suggesting that net lactate production is
beneficial to a tumor because it allows the creation of appropriate
intracellular and extracellular pH microenvironments. We need to
know if this is true also for other types of tumor and to study the
effects, in real time, of inhibiting these, and other, transporters.
Materials and Methods
Ethics statement
All procedures involving animals conformed to European
Council Directive 86/609/EEC and the study was approved by
the Ethical Committee of the Grenoble-Institut des Neurosciences,
agreement ID 004. Facilities for animal housing and procedures
were approved by the French Ministry of Agriculture, licence A 38
516 10008 and all experimenters held personal licenses. Tumor
size was monitored non-invasively by MRI and the rats were
sacrificed before the appearance of marked clinical symptoms.
Preparation of the tumor model
C6 cells [75] from the American Type Culture Collection were
grown in DMEM containing 25 mM glucose and 2 mM L-
glutamine (product 31966-021 from Invitrogen, Cergy Pontoise,
France) to which was added 10% FBS (Invitrogen) and antibiotics.
The rat glioma model was prepared as described [76]: male Wistar
rats (200–230 g) were anesthetized with isoflurane and 10
5 C6
cells in DMEM were injected stereotaxically in the right caudate
nucleus. About 20–25 days after the tumor implantation, the rat
was decapitated, the brain was rapidly removed and frozen in
isopentane at – 80uC, and 10 mm cryosections were cut at 220uC.
Antibodies
In agreement with the vendor’s data sheet, we found that the
monoclonal anti-NHE1 antibody clone 4E9 (Chemicon
MAB3140) did not clearly label sections of brain. In contrast,
strong labeling was observed with antiserum 1950 raised against a
fusion protein of the C-terminal of human NHE1 (pMAL/NHE1/
635-815). This had previously used on pancreatic and kidney
tissue [77] and we further demonstrated its specificity (see
Supporting Information, Text S1, Figure S2).
For MCT1 we used VPA 1286 from Abcys, Paris, at 1/300.
This is a chicken polyclonal antibody raised against a 25 AA
peptide from the cytoplasmic C terminal of rat MCT1. Affinity
purified rabbit anti MCT4 was MCT45-A from Alpha Diagnostic,
San Antonio, used at 1/300. The monoclonal antibody M25
against carbonic anhydrase IX (CAIX) has been described [72].
Secondary antibodies were anti rabbit Alexa 568, anti-mouse
Alexa 488 or anti-chicken Alexa 488, all at 1/500 and from
Invitrogen.
Immunohistochemistry
The sections were fixed for 10 min in 4% paraformaldehyde,
washed and incubated for 1 h in 3% BSA at room temperature,
then incubated with the first antibody in 3% BSA for 16 h at 4uC.
After 3 rinses in PBS, the secondary antibody was applied for 1 h
at room temperature. After three more rinses, the sections were
mounted in GelMount (MM, France) containing bisbenzimide
Hoechst 33342 trichlorohydride.
Imaging
Tile scans were made on a Leica DM6000B microscope with a
TCS SP5 confocal system. For profiles, a x40 oil immersion
objective (Leica HCX PL APO) was used with the numerical
aperture reduced to 0.75 to provide uniform illumination of the
field. The pinhole was set at 200 mm to increase the depth of field
and reduce errors due to changes in the plane of the section, and
each frame was 5126512 pixels. Analysis was done with ImageJ
and GraphPad Prism. To average profiles, the individual raw
profiles were smoothed twice over 13 points and the edge of the
tumor defined as x=0 on a graph of the Hoechst labeling. The
abscissae for the profiles of the other labels (e.g., NHE1 and
MCT1) were shifted by the same amount. The profiles from all the
tumors were averaged, the S.E.M. for each x value being
calculated by Prism.
Supporting Information
Figure S1 Immunolabeling of tissue sections. (A) NHE1
labeling outside a tumor. (B) Negative control (no primary
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PLoS ONE | www.plosone.org 7 February 2011 | Volume 6 | Issue 2 | e17416antibody) on an adjacent section. (C) Higher magnification of
double labeling for NHE1 (red) and MCT1 (green) showing
MCT1 labeling along blood vessels in extratumoral tissue.
(TIF)
Figure S2 Specificity of the anti-NHE1 antiserum. (A)
Western blot of antiserum 1950 on a protein extract of a brain
bearing a C6 glioma showing bands at 95 and 65 kDa. (B) The
preparation of CterNHE1-GST revealed with Coomassie blue in
SDS-PAGE on a 10% gel (a) and revealed on Western blots by
antiserum 1950 (b) and monoclonal antibody 4E9 (c). After
depletion by the NHE1 construct, antiserum 1950 no longer
detected the construct (d). Labeling of brain sections was more
intense with undepleted antiserum 1950 (C) than with the depleted
antiserum (D). Antiserum 1950 did not label the NHE3 isoform in
PS 120 fibroblasts (E). WT fibroblasts transfected to express NHE1
show a band at the appropriate MWt (arrow), whereas this is not
present for WT fibroblasts and fibroblasts transfected to express
NHE3. Scale bars in (C,D) 100 mm.
(TIF)
Text S1 Tests showing the efficacy of the anti-NHE1
antiserum.
(DOC)
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